BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

NCT03355976 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Extra Renal Origin
Clear Cell Adenocarcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Brown University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]